Table 6.
Treatment class | Current NP‐based therapies | Current deficiencies | What is DNA offering | Examples | Ref |
---|---|---|---|---|---|
Drug delivery | NPs, liposomes, albumin bound, PEGylation | Renal clearance, low tumor penetration, system toxicity, MDR | Specificity, high tumor penetration, overcome MDR | Dox delivery using DNA structures, metal‐complex drug delivery | [[qv: 25,48a,51c,73a,76,77,81,87b,144]] |
Protein/enzyme delivery | NPs, liposomes, albumin bound, PEGylation | Renal clearance, limited cellular internalization, stability | Specificity, cellular uptake | Thrombin delivery | [[qv: 48c,145]] |
Immunostimulation and vaccines | Inactivated whole organisms, virus‐like particles | Low specificity, cell internalization deficiency | Vehicle to cross cell membrane | DNA triangle‐assisted delivery of CpG sequences, tetrahedral‐antigen precursor activator | [[qv: 58,74a]] |
Gene therapy | NPs, viral capsules | Cell internalization, transport to the nucleus | Improved drug retention in cells | DNA structure‐assisted delivery of miRNA, siRNA,DNAzymes | 52, 61, 77, 146 |
Combinatorial therapy | – | Controlled attachment of different therapeutic agents | Substrate to attach various NPs and biomolecules | DNA structure‐directed assembly of AuNR‐based photodynamic therapy | [[qv: 87a,144c,147]] |
MDR, multidrug resistance; PEG, polyethylene glycol; miRNA, microRNA; siRNA, small interfering RNA.